Delivery Order SPE2DR25D2205-SPE2DR26F1F29
- Not listed
- The Defense Logistics Agency awarded a $14,337.77 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on November 10, 2025, with an ultimate completion date of November 12, 2025. This is a non-set-aside award representing a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical distributor,...
- The Defense Logistics Agency awarded a $16,998.05 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 14, 2025, with completion scheduled for July 15, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The delivery is scheduled to occur at AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $12,257.90 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on November 4, 2025, with an ultimate completion date of November 5, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating it was awarded through open competition. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents...
- The Defense Logistics Agency awarded a $61,467.35 delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on November 3, 2025, with a completion date of November 4, 2025. This non-competitive, firm fixed-price delivery order represents a single-source procurement under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The company, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $6,837.84 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 26, 2025, with completion scheduled for August 27, 2025. This competitively awarded, firm fixed-price delivery order represents a single transaction under AmerisourceBergen's larger pharmaceutical supply contract vehicle with DLA. The product will be delivered to the company's corporate headquarters in Conshohocken,...
- The Defense Logistics Agency awarded a $17,619.85 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 23, 2025, with completion scheduled for July 24, 2025. This firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The work will be performed at AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency awarded a delivery order valued at $22,023.57 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on November 6, 2025, with an ultimate completion date of November 7, 2025. This firm fixed-price, competitively awarded delivery order represents a single transaction under AmerisourceBergen's larger pharmaceutical supply relationship with the federal government. The order will be fulfilled from the vendor's corporate office location in...
- The Defense Logistics Agency awarded a $7,684.68 delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors (2 ml). This competitively awarded, firm fixed-price contract is classified as a child delivery order without set-aside designation and is scheduled for completion by June 3, 2025. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $5,987.47 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitive award, issued under firm fixed pricing, represents a child contract to AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency awarded a $10,295.32 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Dupixent 300 mg/2 mL pen auto-injectors. The contract, which is classified as a child order under a larger vehicle, carries an ultimate completion date of September 17, 2025, and represents a competitive award with no set-aside designation. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This...
- SPE2DR25D2205Indefinite Delivery Contract
- SPE2DR25D2205-SPE2DR26F1F29Delivery Order
The Defense Logistics Agency awarded a $82,694.76 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on November 3, 2025, with an ultimate completion date of November 4, 2025. This is a non-set-aside competitively awarded contract for pharmaceutical supply to support federal medical procurement needs. The award was executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and serves as a child delivery order under the company's broader contract vehicle with the Defense Logistics Agency. This delivery order is issued under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and running through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to military healthcare programs and other federal customers including the Defense Health Agency and U.S. Coast Guard. Dupixent is a specialty biologic medication used for treating atopic dermatitis, asthma, and eosinophilic conditions, reflecting the company's capability to deliver high-value specialty pharmaceuticals across multiple therapeutic domains in support of federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $82.7k | 11/3/25 |